Conducting Clinical Research In Chronic Kidney Disease
Funder
National Health and Medical Research Council
Funding Amount
$569,219.00
Summary
The burden of Chronic Kidney Disease (CKD) is large, increasing, and ultimately unsustainable. One in ten Australians have CKD which puts them at higher risk of cardiovascular disease and cancer, and a higher likelihood of an early death. CKD also has a negative impact on people's lifestyles and relationships. Practitioner Fellowship support will allow me relief from my clinical commitments to invest in promising lines of new enquiry to support people with CKD and their carers.
Improving Transplant Outcomes Through Translational Research
Funder
National Health and Medical Research Council
Funding Amount
$406,585.00
Summary
The aim of my research is to improve transplant outcomes by developing novel, clinically realistic, therapeutic options for patients with end-organ failure and for a specific cohort of patients with type 1 diabetes. The goal is to advance transplantation by developing a strong interactive research environment where initiatives are quickly interchanged between the laboratory and the clinic. These include novel trials in islet transplantation and use of genomics to improve transplant outcomes.
The Generation Of High Quality Evidence In Critical Care Medicine Through Multicentre Randomized Controleld Trials And Its Translation Into Practice
Funder
National Health and Medical Research Council
Funding Amount
$240,121.00
Summary
This research program will establish new approaches to sepsis, traumatic brain injury, kidney protection, transfusion, post-operative care, sedation, antibiotics and mobilization of acutely ill patients. Experimental research will help understand why the kidney malfunctions during severe infection. Database investigations will identify of successful patterns of treatment and potential new fields of investigations. Informatics based studies will use electronic data to develop decision support sys ....This research program will establish new approaches to sepsis, traumatic brain injury, kidney protection, transfusion, post-operative care, sedation, antibiotics and mobilization of acutely ill patients. Experimental research will help understand why the kidney malfunctions during severe infection. Database investigations will identify of successful patterns of treatment and potential new fields of investigations. Informatics based studies will use electronic data to develop decision support systems to improve patient care.Read moreRead less
Development Of Systemic Therapies To Improve Response And Prevent Resistance In The Treatment Of Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$569,219.00
Summary
This program of research utilises the unique resources at Melanoma Institute Australia (MIA) to understand the biology of prolonged response and resistance to novel drug therapies used in metastatic melanoma, a cancer that now leads the field in the discovery of new targets for therapeutic manipulation. This program also aims to create new methods to efficiently test and develop drug therapy combinations in humans to improve patient outcomes further or prevent metastatic melanoma altogether.
I am an orthopaedic surgeon and clinician-scientist based at Sydney’s largest children’s hospital. My goal is to improve treatments for children with traumatic injuries and bone deformity. I have worked in bone research for over 20 years. My current research interests are finding new treatments for drug-resistant bacterial infections, treating genetic bone disease, and developing new medical devices to help children’s bones grow straight.
Neurobiology Of Childhood Speech And Language Disorders: Advancing Diagnosis, Prognosis And Management
Funder
National Health and Medical Research Council
Funding Amount
$467,961.00
Summary
Half a million Australian children have a speech/language disorder, tripling their changes of poor academic outcomes, limited employment options and social isolation. Current speech therapy is outdated, focusing on symptoms and ignoring important evidence on underlying aetiologies. I will transform detection, diagnosis and treatment of speech/language disorders to optimise patient outcomes, by identifying and translating findings on genes and brain pathways leading to these conditions.
Major advances in cancer treatment has been made by identifying gene mutations in cancers to which the cancer is “addicted”, such that turning off the effects of the mutations leads to death of the cancer cells. Grant McArthur has been successful in applying this principle to rare types of sarcoma bringing his work to routine clinical practice globally. In this application he will investigate targeting the BRAF, KIT and MYC genes focusing on melanoma, a major cancer problem in Australia.
Immunopathogenesis And Manipulation Of The HIV Reservoir
Funder
National Health and Medical Research Council
Funding Amount
$494,732.00
Summary
Kelleher is a Clinical immunologist with a globally recognised, sustained track record of translational research which has impacted both on our understanding of HIV immunopathogenesis and on the way HIV infection is treated. He will conduct a series of studies that encompass basic scientific techniques through to pivotal pre-clinical and clinical studies that will provide a pathway towards control of HIV-infection without daily therapy.
Hepatitis C Vaccines: Preclinical To Clinical Development
Funder
National Health and Medical Research Council
Funding Amount
$474,244.00
Summary
Hepatitis C is one of the most common notifiable infectious diseases in Australia with 200,000 infected individuals and 10,000 new infections each year. Treatments currently available for hepatitis C are effective but also associated with significant side effects and expensive. The economic and health burden of hepatitis C infection and the high costs of emerging antiviral therapies makes the development of an effective vaccine for HCV imperative. This project aims to develop a vaccine for the p ....Hepatitis C is one of the most common notifiable infectious diseases in Australia with 200,000 infected individuals and 10,000 new infections each year. Treatments currently available for hepatitis C are effective but also associated with significant side effects and expensive. The economic and health burden of hepatitis C infection and the high costs of emerging antiviral therapies makes the development of an effective vaccine for HCV imperative. This project aims to develop a vaccine for the prevention of hepatitis C infection.Read moreRead less
Professor Elizabeth Elliott AM is an international leader in rare disease research, as Director of the Australian Paediatric Surveillance Unit and investigator on The Lililwan project in Fitzroy Valley's remote Aboriginal communities, WA. This will establish prevalence of Fetal Alcohol Spectrum Disorders (FASD); diagnose and manage affected children and support their carers; and provide data to inform service needs for FASD and prevention policy for alcohol use pregnancy.